Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.

Literature DB >> 23639782

Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.

Xuejun Wang.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2013 PMID： 23639782 PMCID： PMC3661019 DOI： 10.1093/eurjhf/hft069

Source DB: PubMed Journal: Eur J Heart Fail ISSN： 1388-9842 Impact factor: 15.534

× No keyword cloud information.

15 in total

1. Enhancement of proteasome function by PA28α overexpression protects against oxidative stress.

Authors: Jie Li; Saul R Powell; Xuejun Wang
Journal: FASEB J Date: 2010-11-23 Impact factor: 5.191

Review 2. Proteasome inhibitors and cardiac cell growth.

Authors: Nadia Hedhli; Christophe Depre
Journal: Cardiovasc Res Date: 2009-07-03 Impact factor: 10.787

3. Unexpected cardiotoxicity in haematological bortezomib treated patients.

Authors: Orciuolo Enrico; Buda Gabriele; Cecconi Nadia; Galimberti Sara; Versari Daniele; Cervetti Giulia; Salvetti Antonio; Petrini Mario
Journal: Br J Haematol Date: 2007-06-11 Impact factor: 6.998

Review 4. Proteasome functional insufficiency in cardiac pathogenesis.

Authors: Xuejun Wang; Jie Li; Hanqiao Zheng; Huabo Su; Saul R Powell
Journal: Am J Physiol Heart Circ Physiol Date: 2011-09-23 Impact factor: 4.733

5. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice.

Authors: Zongwen Tian; Hanqiao Zheng; Jie Li; Yifan Li; Huabo Su; Xuejun Wang
Journal: Circ Res Date: 2012-06-26 Impact factor: 17.367

6. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal: N Engl J Med Date: 2005-06-16 Impact factor: 91.245

7. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice.

Authors: Jie Li; Kathleen M Horak; Huabo Su; Atsushi Sanbe; Jeffrey Robbins; Xuejun Wang
Journal: J Clin Invest Date: 2011-08-15 Impact factor: 14.808

8. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.

Authors: Mingxin Tang; Jie Li; Wei Huang; Huabo Su; Qiangrong Liang; Zongwen Tian; Kathleen M Horak; Jeffery D Molkentin; Xuejun Wang
Journal: Cardiovasc Res Date: 2010-07-02 Impact factor: 10.787

Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.

1. Enhancement of proteasome function by PA28α overexpression protects against oxidative stress.

Review 2. Proteasome inhibitors and cardiac cell growth.

3. Unexpected cardiotoxicity in haematological bortezomib treated patients.

Review 4. Proteasome functional insufficiency in cardiac pathogenesis.

5. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice.

6. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

7. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice.

8. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.

Review 9. Proteasome inhibition during myocardial infarction.

Review 10. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.

1. Gambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-κB pathway.

Review 2. Proteasome dysfunction in cardiomyopathies.

Review 3. Proteasomal and lysosomal protein degradation and heart disease.

4. Delineation of Molecular Pathways Involved in Cardiomyopathies Caused by Troponin T Mutations.